Currently, the global increase in resistance of pathogens to widely used antibiotics requires a return to the practice of using some classic drugs with preserved activity, finding new ways and directions of delivery of antibiotics to the locations of pathogenic microorganisms and the use of antimicrobial drugs that are not yet resistant. Doxycycline refers to antimicrobial drugs that do not yet have widespread resistance. Numerous studies of doxycycline have now been described as enhancing therapeutic effects, including COVID-19-related diseases, and finding new delivery routes to limit systemic side effects associated with high doses and avoid antibiotic resistance. The aim of the work was to analyze modern ways of doxycycline delivery, to determine the prospects for use in pharmacy, to summarize and systematize data on its functional purpose in the development of drugs with specified pharmaco-technological parameters. It is established that in the Ukrainian pharmaceutical market the range of drugs based on doxycycline hyclate is represented only by solid oral dosage forms - tablets and capsules for immediate release, but in the global pharmaceutical market there are additional dosage forms that provide parenteral delivery of doxycycline and oral forms. suspensions, syrups, dispersed tablets and delayed-release dosage forms – tablets, capsules and granules, which are the basis for the development of domestic drugs based on doxycycline. Development of new dosage forms with modified DH, such as implants, aerosols, lyophilisate for solution for injection, development of new manufacturing technologies, selection of excipients and delivery systems can improve the pharmacological action of antibiotics by reducing the dose and frequency of administration, prolonged or controlled programming. , and expanding the range of therapeutic action. Doxycycline is promising in pharmaceutical practice for the treatment of COVID-19, both due to its ability to inhibit matrix metalloproteinases (MMPs) and antiviral activity, especially against Mycoplasma pneumoniae, which is a secondary bacterial cause of pneumonia during the COVID-19 pandemic.